Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: A pilot study

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 136-147

  Katsiki, Niki ^a,b   Mikhailidis, Dimitri P ^b   Gotzamani Psarrakou, Anna ^a   Didangelos, Triantafillos P ^a   Yovos, John G ^a   Karamitsos, Dimitrios T ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Gender; Glycosylated haemoglobin A1c; Insulin; Type 2 diabetes mellitus; Weight gain

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; INSULIN; LEPTIN; NEUROPEPTIDE Y;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80053581359     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010136     Document Type: Article

References (56)

1. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diab Res Clin Pract 2004; 65S: S23-7.
2. United Kingdom Prospective Diabetes Study. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
3. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.
4. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001; 2: 282-6.
5. Yki-Järvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037-43.
6. Porte D Jr, Baskin DG, Schwartz MW. Insulin signalling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005; 54: 1264-76.
7. Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med 2001; 226: 963-77.
8. Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of foods intake. Physiol Rev 2005; 85: 1131-58.
9. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009; 20: 831-9.
10. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
11. Kim HJ, Kim SK, Shim WS, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 81: 42-9.
12. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: 646-50.
13. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and highdensity lipoprotein cholesterol levels in type 2 diabetes. Endocr J2009; 56: 691-8.
14. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 373-9.
15. Ariyasu H, Takaya K, Hosoda H, et al. Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002; 143: 3341-50.
16. Murakami N, Hayashida T, Kuroiwa T, et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002; 174: 283-8.
17. Kusuoka H, Hoffman J. Advice on statistical analysis for circulation research. Circ Res 2002; 91: 662-71.
18. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPDS 20: plasma leptin, obesity and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997; 82: 654-7.
19. Schäffler A, Herfarth H, Paul G, et al. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes 2004; 112: 383-9.
20. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009; 16: 113-8.
21. Ludescher B, Machann J, Eschweiler GW, et al. Correlation of fat distribution in whole body MRI with generally used anthropometric data. Invest Radiol 2009; 44: 712-9.
22. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-41.
23. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes and monodrug therapy. Metabolism 2004; 53: 1454-61.
24. Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance and high-density lipoprotein cholesterol, but not with gender, menopausal status or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88: 5747-52.
25. Greenman Y, Rouach V, Limor R, Gilad S, Stern N. Testosterone is a strong correlate of ghrelin levels in men and postmenopausal women. Neuroendocrinology 2009; 89: 79-85.
26. Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J2007; 54: 895-902.
27. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia ands insulin resistance in patients with type2 diabetes mellitus. Eur J Endocrinol 2004; 151: 573-7.
28. Vaverkova H, Chlup R, Ficker L, Novotny D, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105(Suppl 2): 74-7.
29. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9: 386-93.
30. Aas AM, Hanssen KF, Berg JP, Thorsby PM, Birkeland KI. Insulin- stimulated increase in serum leptin levels precedes and correlates with weight gain during insulin therapy in type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2900-6.
31. Aas AM, Seljeflot I, Torjesen PA, Diep LM, Thorsby PM, Birkeland KI. Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 2006; 49: 872-80.
32. Carey PE, Stewart MW, Ashworth L, Taylor R. Effect of insulin therapy on plasma leptin and body weight in patient with type 2 diabetes. Horm Metab Res 2003; 35: 372-6.
33. Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008; 7: 16.
34. Kos K, Harte AL, James S, et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endocrinol Metab 2007; 293: E1335-40.
35. Ahima RS, Qi Y, Singhal NS. Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res 2006; 153: 155-74.
36. Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am J Physiol 1999; 276: E479-82.
37. Zukowska Z, Grant DS, Lee EW. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 2003; 13: 86-92.
38. McDermott BJ, Bell D. NPY and cardiac diseases. Curr Top Med Chem 2007; 7: 1692-703.
39. Akagi S, Nagake Y, Sugimoto T, et al. Plasma neuropeptide Y concentrations in patients on hemodialysis. Nephron 2002; 92: 333-8.
40. Hickey MS, Israel RG, Gardiner SN, et al. Gender differences in serum leptin levels in humans. Biochem Mol Med 1996; 59: 1-6.
41. Marita AR, Sarkar JA, Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol Cell Biochem 2005; 275: 143-51.
42. Lele RD, Joshi SR, Gupte A. Association of adipocytokines (leptin, adiponectin, TNF-alpha), insulin and proinsulin with diabetes- the Mumbai Obesity Project (MOP). J Assoc Physicians India 2006; 54: 689-96.
43. Torchinsky MY, Gomez R, Rao J, Vargas A, Mercante DE, Chalew SA. Poor glycemic control is associated with increased diastolic blood pressure and heart rate in children with Type 1 diabetes. J Diabetes Complications 2004; 18: 220-3.
44. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications 1987; 1: 91-5.
45. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011; 15: 401-20.
46. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007; 145: 52-5.
47. Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M. Metformin increases plasma ghrelin in type 2 diabetes. Br J Clin Pharmacol 2009; 68: 875-82.
48. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009, 58: 143-8.
49. Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 210-4.
50. Derosa G, Cicero AF, D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849-56.
51. Fuke Y, Fujita T, Satomura A, Wada Y, Matsumoto K. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Diabetes Technol Ther 2010; 12: 393-8.
52. Nomura S, Inami N, Kimura Y, et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21: 38-44.
53. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003; 14: 357-60.
54. von Eynatten M, Schneider JG, Hadziselimovic S, et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 2005; 28: 754-5.
55. Hu Y, Tong G, Xu W, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009; 6: 262-8.
56. Otto C, Otto B, Frost RJ, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007; 44: 65-8.